ImmuLogic Pharmaceutical IPO: Financial Ratio Analysis
This paper analyzes the financial position of ImmuLogic Pharmaceutical Corporation, a four-year-old biotech firm that had yet to bring a commercially viable product to market, as it considered proceeding with an initial public offering (IPO) targeting $80 million in capital. Using data drawn from the company's financial statements for 1989 and 1990, the paper computes key financial ratios — including the quick ratio, current ratio, asset turnover, and return on assets — to assess the firm's short-term liquidity and profitability trajectory. The analysis projects forward four years under the same deterioration rates, demonstrating that without the IPO proceeds, the company faces exponential losses and severe asset depletion. The paper ultimately argues that proceeding with the IPO is financially necessary and strategically sound.
- Introduction and Background: ImmuLogic's market context and IPO question
- Liquidity Ratios: Quick Ratio and Current Ratio: Short-term liquidity calculations for 1989 and 1990
- Asset Turnover and Return on Assets: Efficiency and profitability ratios reveal declining performance
- Financial Projections and Sustainability Analysis: Four-year projections show exponential losses ahead
- Conclusion: The Case for Proceeding with the IPO: IPO advantages justify proceeding with equity offering
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- It grounds every recommendation in concrete numerical calculations drawn directly from the firm's financial statements, giving the argument an objective, evidence-based foundation.
- The forward projection section is particularly persuasive: by extrapolating the existing deterioration rates over four years, the paper makes the cost of inaction vivid and quantifiable rather than merely abstract.
- The paper appropriately acknowledges limitations — for instance, noting that certain ratios such as debt-to-equity cannot be computed due to the absence of existing equity — which adds analytical credibility.
Key academic technique demonstrated
The paper demonstrates applied financial ratio analysis as a decision-support tool. Rather than treating ratios as isolated metrics, the author sequences them — liquidity first, then efficiency, then profitability — to build a cumulative picture of organizational health. The projection methodology, which applies historical decline rates to forecast future asset and loss figures, illustrates how historical financial data can be used to model risk scenarios for investment decisions.
Structure breakdown
The paper opens with a brief contextual introduction establishing the firm's situation and the central question. It then moves through four financial computations in a structured format (formula, calculation, interpretation). A synthesis section follows that identifies the overall deteriorating trend, after which a four-year projection is built to stress-test the no-IPO scenario. The paper closes with a bulleted list of strategic advantages supporting the IPO decision, converting quantitative findings into actionable recommendations.
Introduction and Background
ImmuLogic Pharmaceutical Corporation is a relatively young firm with only four years of experience in the market. The organization nevertheless possesses significant growth potential and has decided to pursue an initial public offering (IPO) in an effort to generate an expected $80 million in capital. However, in a context where the firm does not yet have a commercially viable product — and bringing one to market would require an additional four years — serious questions arise regarding the future sustainability of the offering. Specifically, the company's executives are weighing whether to proceed with the IPO or withdraw it.
Providing a well-grounded answer to this question is an intricate endeavor, dependent on a multitude of factors. At the initial level, however, the analysis relies on objective quantitative features conducted through numerical data, which lead to relevant and unbiased conclusions (Balnaves and Caputi, 2001). Several financial computations are completed to assess the financial strength of ImmuLogic Pharmaceutical Corporation, using data collected from the firm's financial statements.
Liquidity Ratios: Quick Ratio and Current Ratio
a) Quick Ratio
Quick ratio = (Current assets − Inventories) / Current liabilities
Note: Since ImmuLogic Pharmaceutical Corporation does not have a commercially viable product, its inventories are assumed to be zero.
Quick ratio = Current assets / Current liabilities
Quick ratio in 1989 = 20,466 / 877 = 23.34
Quick ratio in 1990 = 15,142 / 890 = 17.01
The quick ratio portrays the company's short-term liquidity — specifically, its ability to pay short-term obligations with its most liquid assets (Investopedia, 2012). The computation of both years' ratios reveals that the company's ability to pay its short-term debts decreased in 1990 relative to the previous year.
b) Current Ratio
Current ratio = Current assets / Current liabilities
Note: Since ImmuLogic Pharmaceutical Corporation does not carry inventories, its current ratio equals its quick ratio, as follows:
Current ratio in 1989 = 20,466 / 877 = 23.34
Current ratio in 1990 = 15,142 / 890 = 17.01
The current ratio, also known as the liquidity ratio, is an indicator of a company's ability to pay its short-term obligations (Investopedia, 2012). As these computations reveal, the pharmaceutical company encountered a decline in its ability to honor short-term obligations in 1990 relative to the previous year. Nevertheless, both ratios remain very high, indicating that the firm retained substantial liquidity in the near term.
Already a member? Log in
Unlock the rest of this paper
135,000+ research papers · AI writing tools · Plagiarism & AI detection
7-Day Pass
Does not renew
Get 7-Day PassMonthly
Renews at $12.99/month until canceled
Start MonthlyAnnual
Renews at $99/year until canceled
Start Annual- Unlimited AI writing tools
- Plagiarism and AI text detection tool
Plan details
Unlimited AI writing tools are for individual, non-automated use and are subject to our Terms of Service and abuse-prevention measures.
TextChecker scans: 3 during the 7-Day Pass, or 5 per month with Monthly and Annual.
Prices exclude applicable tax.
Always verify citation format against your institution’s current style guide requirements.